Skip to main content

Table 3 The risk of recurrence in ICC patients according to the expression of Beclin-1, ARID1A, IDH1 and CA9

From: High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study

IHC intensity

Follow-up (Month)

Number of Recurrence

Rate, n/1000 person-month

Crude HR (95% CI)

Beclin-1

 0

581.14

8

13.77

1.0

 1

812.20

22

27.09

1.55 (0.69–3.50)

 2

496.95

35

70.43

2.75 (1.26–6.00)

 3

310.27

20

64.46

3.19 (1.38–7.37)

 Negative

581.14

8

13.77

1.0

 Positive

1619.42

77

47.55

2.27 (1.09–4.75)

ARID1A

 0

994.59

23

23.13

1.0

 1

641.70

34

52.98

1.73 (1.01–2.94)

 2

480.94

23

47.82

1.76 (0.98–3.14)

 3

83.33

5

60.00

1.47 (0.56–3.89)

 Negative

994.59

23

23.13

1.0

 Positive

1205.97

62

51.41

1.71 (1.06–2.78)

IDH1

 0

258.99

5

19.31

1.0

 1

418.98

20

47.74

1.56 (0.58–4.16)

 2

1071.72

35

32.66

1.14 (0.44–2.90)

 3

450.87

25

55.45

1.38 (0.53–3.63)

 Negative

258.99

5

19.31

1.0

 Positive

1941.57

80

41.20

1.29 (0.52–3.20)

CA9

 0

541.80

12

22.15

1.0

 1

420.68

26

61.80

1.12 (0.56–2.23)

 2

695.73

27

38.81

0.88 (0.44–1.75)

 3

542.35

20

36.88

0.91 (0.44–1.86)

 Negative

541.80

12

22.15

1.0

 Positive

1658.76

73

44.01

0.96 (0.52–1.77)

  1. Bold indicates statistical significance, p < 0.05